GB2337933A - Treating or prophylaxis of smoking related diseases - Google Patents
Treating or prophylaxis of smoking related diseases Download PDFInfo
- Publication number
- GB2337933A GB2337933A GB9811908A GB9811908A GB2337933A GB 2337933 A GB2337933 A GB 2337933A GB 9811908 A GB9811908 A GB 9811908A GB 9811908 A GB9811908 A GB 9811908A GB 2337933 A GB2337933 A GB 2337933A
- Authority
- GB
- United Kingdom
- Prior art keywords
- preparation
- vitamin
- substances
- rda
- preparation according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000000391 smoking effect Effects 0.000 title claims abstract description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 19
- 201000010099 disease Diseases 0.000 title claims description 14
- 238000011321 prophylaxis Methods 0.000 title 1
- 238000002360 preparation method Methods 0.000 claims abstract description 56
- 229940088594 vitamin Drugs 0.000 claims abstract description 28
- 239000011782 vitamin Substances 0.000 claims abstract description 28
- 239000000126 substance Substances 0.000 claims abstract description 26
- 229930003231 vitamin Natural products 0.000 claims abstract description 25
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 24
- 239000011707 mineral Substances 0.000 claims abstract description 24
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 23
- 235000013343 vitamin Nutrition 0.000 claims abstract description 23
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 21
- 235000009508 confectionery Nutrition 0.000 claims abstract description 9
- 230000009286 beneficial effect Effects 0.000 claims abstract description 6
- 235000010755 mineral Nutrition 0.000 claims description 22
- 235000006708 antioxidants Nutrition 0.000 claims description 20
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 18
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 16
- 239000003826 tablet Substances 0.000 claims description 15
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 14
- 239000013589 supplement Substances 0.000 claims description 14
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 12
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 9
- 229930003268 Vitamin C Natural products 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 235000019154 vitamin C Nutrition 0.000 claims description 9
- 239000011718 vitamin C Substances 0.000 claims description 9
- 229930003427 Vitamin E Natural products 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 8
- 235000019165 vitamin E Nutrition 0.000 claims description 8
- 229940046009 vitamin E Drugs 0.000 claims description 8
- 239000011709 vitamin E Substances 0.000 claims description 8
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 7
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 7
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 7
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 7
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 7
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 7
- 235000013734 beta-carotene Nutrition 0.000 claims description 7
- 239000011648 beta-carotene Substances 0.000 claims description 7
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 7
- 229960002747 betacarotene Drugs 0.000 claims description 7
- 229960000304 folic acid Drugs 0.000 claims description 7
- 235000019152 folic acid Nutrition 0.000 claims description 7
- 239000011724 folic acid Substances 0.000 claims description 7
- 229960002477 riboflavin Drugs 0.000 claims description 7
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 6
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 6
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 6
- -1 1. 6mg) Chemical compound 0.000 claims description 5
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 235000003599 food sweetener Nutrition 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 235000011649 selenium Nutrition 0.000 claims description 5
- 239000011669 selenium Substances 0.000 claims description 5
- 229910052711 selenium Inorganic materials 0.000 claims description 5
- 239000003765 sweetening agent Substances 0.000 claims description 5
- 239000011701 zinc Substances 0.000 claims description 5
- 229910052725 zinc Inorganic materials 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 4
- 229930003316 Vitamin D Natural products 0.000 claims description 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 235000001465 calcium Nutrition 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000007937 lozenge Substances 0.000 claims description 4
- 229910052748 manganese Inorganic materials 0.000 claims description 4
- 239000011572 manganese Substances 0.000 claims description 4
- 235000017802 other dietary supplement Nutrition 0.000 claims description 4
- 235000019192 riboflavin Nutrition 0.000 claims description 4
- 239000002151 riboflavin Substances 0.000 claims description 4
- 235000019166 vitamin D Nutrition 0.000 claims description 4
- 239000011710 vitamin D Substances 0.000 claims description 4
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 4
- 229940046008 vitamin d Drugs 0.000 claims description 4
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 3
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 3
- 229930003270 Vitamin B Natural products 0.000 claims description 3
- 229930003779 Vitamin B12 Natural products 0.000 claims description 3
- 229930003471 Vitamin B2 Natural products 0.000 claims description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 3
- 229960002685 biotin Drugs 0.000 claims description 3
- 235000020958 biotin Nutrition 0.000 claims description 3
- 239000011616 biotin Substances 0.000 claims description 3
- 229960002715 nicotine Drugs 0.000 claims description 3
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 3
- 229960003512 nicotinic acid Drugs 0.000 claims description 3
- 235000001968 nicotinic acid Nutrition 0.000 claims description 3
- 239000011664 nicotinic acid Substances 0.000 claims description 3
- 229940055726 pantothenic acid Drugs 0.000 claims description 3
- 235000019161 pantothenic acid Nutrition 0.000 claims description 3
- 239000011713 pantothenic acid Substances 0.000 claims description 3
- 235000010603 pastilles Nutrition 0.000 claims description 3
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 3
- 239000002516 radical scavenger Substances 0.000 claims description 3
- 235000019157 thiamine Nutrition 0.000 claims description 3
- 239000011721 thiamine Substances 0.000 claims description 3
- 235000019155 vitamin A Nutrition 0.000 claims description 3
- 239000011719 vitamin A Substances 0.000 claims description 3
- 235000019156 vitamin B Nutrition 0.000 claims description 3
- 239000011720 vitamin B Substances 0.000 claims description 3
- 235000019163 vitamin B12 Nutrition 0.000 claims description 3
- 239000011715 vitamin B12 Substances 0.000 claims description 3
- 235000019164 vitamin B2 Nutrition 0.000 claims description 3
- 239000011716 vitamin B2 Substances 0.000 claims description 3
- 235000019158 vitamin B6 Nutrition 0.000 claims description 3
- 239000011726 vitamin B6 Substances 0.000 claims description 3
- 229940045997 vitamin a Drugs 0.000 claims description 3
- 229940011671 vitamin b6 Drugs 0.000 claims description 3
- 235000014749 Mentha crispa Nutrition 0.000 claims description 2
- 244000246386 Mentha pulegium Species 0.000 claims description 2
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 2
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 2
- 235000001050 hortel pimenta Nutrition 0.000 claims description 2
- 235000019629 palatability Nutrition 0.000 claims description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 4
- 229940069428 antacid Drugs 0.000 claims 3
- 239000003159 antacid agent Substances 0.000 claims 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 2
- 229940123457 Free radical scavenger Drugs 0.000 claims 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 2
- 239000000443 aerosol Substances 0.000 claims 2
- 229940008126 aerosol Drugs 0.000 claims 2
- 235000015895 biscuits Nutrition 0.000 claims 2
- 235000012411 boiled sweets Nutrition 0.000 claims 2
- 235000012970 cakes Nutrition 0.000 claims 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims 2
- 235000014510 cooky Nutrition 0.000 claims 2
- 229910052802 copper Inorganic materials 0.000 claims 2
- 239000010949 copper Substances 0.000 claims 2
- 239000003792 electrolyte Substances 0.000 claims 2
- 235000013305 food Nutrition 0.000 claims 2
- 239000011630 iodine Substances 0.000 claims 2
- 229910052740 iodine Inorganic materials 0.000 claims 2
- 229910052742 iron Inorganic materials 0.000 claims 2
- 239000011777 magnesium Substances 0.000 claims 2
- 229910052749 magnesium Inorganic materials 0.000 claims 2
- 159000000003 magnesium salts Chemical class 0.000 claims 2
- 239000002324 mouth wash Substances 0.000 claims 2
- 229940051866 mouthwash Drugs 0.000 claims 2
- 235000014594 pastries Nutrition 0.000 claims 2
- 239000003223 protective agent Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 150000003342 selenium Chemical class 0.000 claims 2
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 2
- 229940034610 toothpaste Drugs 0.000 claims 2
- 239000000606 toothpaste Substances 0.000 claims 2
- 150000003751 zinc Chemical class 0.000 claims 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims 1
- 241000723346 Cinnamomum camphora Species 0.000 claims 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims 1
- 244000166124 Eucalyptus globulus Species 0.000 claims 1
- 244000024873 Mentha crispa Species 0.000 claims 1
- 229960000846 camphor Drugs 0.000 claims 1
- 229930008380 camphor Natural products 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 239000008369 fruit flavor Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 230000000873 masking effect Effects 0.000 claims 1
- 229940041616 menthol Drugs 0.000 claims 1
- 230000003239 periodontal effect Effects 0.000 claims 1
- 235000019587 texture Nutrition 0.000 claims 1
- 241000208125 Nicotiana Species 0.000 abstract description 26
- 235000002637 Nicotiana tabacum Nutrition 0.000 abstract description 26
- 235000015218 chewing gum Nutrition 0.000 abstract description 17
- 229940112822 chewing gum Drugs 0.000 abstract description 17
- 239000008376 breath freshener Substances 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 5
- 235000004251 balanced diet Nutrition 0.000 abstract 1
- 239000000779 smoke Substances 0.000 description 18
- 239000000203 mixture Substances 0.000 description 16
- 230000036541 health Effects 0.000 description 11
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 11
- 239000003344 environmental pollutant Substances 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 9
- 238000009472 formulation Methods 0.000 description 8
- 231100000719 pollutant Toxicity 0.000 description 8
- 230000008901 benefit Effects 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 230000037213 diet Effects 0.000 description 6
- 230000009931 harmful effect Effects 0.000 description 6
- 230000003244 pro-oxidative effect Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000005779 cell damage Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000009469 supplementation Effects 0.000 description 5
- 230000001502 supplementing effect Effects 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 231100000765 toxin Toxicity 0.000 description 5
- 108700012359 toxins Proteins 0.000 description 5
- 231100000357 carcinogen Toxicity 0.000 description 4
- 239000003183 carcinogenic agent Substances 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 230000009245 menopause Effects 0.000 description 4
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 206010013911 Dysgeusia Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000003915 air pollution Methods 0.000 description 2
- 230000002738 anti-smoking effect Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 235000020786 mineral supplement Nutrition 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 235000012094 sugar confectionery Nutrition 0.000 description 2
- 229940045999 vitamin b 12 Drugs 0.000 description 2
- 235000019195 vitamin supplement Nutrition 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 244000078639 Mentha spicata Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 108010003541 Platelet Activating Factor Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 150000003868 ammonium compounds Chemical class 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000015496 breakfast cereal Nutrition 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 231100000317 environmental toxin Toxicity 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
- 230000008376 long-term health Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 231100000516 lung damage Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 229940029985 mineral supplement Drugs 0.000 description 1
- 239000008368 mint flavor Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 150000004005 nitrosamines Chemical class 0.000 description 1
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 1
- 235000015145 nougat Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 235000017924 poor diet Nutrition 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000003331 prothrombotic effect Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 229940100890 silver compound Drugs 0.000 description 1
- 150000003379 silver compounds Chemical class 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 235000015149 toffees Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G4/00—Chewing gum
- A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
- A23G4/064—Chewing gum characterised by the composition containing organic or inorganic compounds containing inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G4/00—Chewing gum
- A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
- A23G4/12—Chewing gum characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G4/126—Chewing gum characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing vitamins, antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/10—Chemical features of tobacco products or tobacco substitutes
- A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A61K9/0058—Chewing gums
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
This invention relates to confectionery and other edible preparations such as chewing gum, sweets or tablets fortified with a proportion of the recommended daily allowance of dietary supplements or other beneficial substances, especially vitamins, minerals and antioxidants. One such form of the preparation may be a breath freshener taken prior to, during or after smoking tobacco. This will ensure that a habit of association will be formed, linking the use of the preparation with the habit of smoking. This may have the effect of ensuring or encouraging use of the preparation on a regular basis thereby providing an enhanced or more balanced diet.
Description
1 Method and composition for dietary supplements 2337933
Technical field
This invention relates to a method and composition for the administration of dietary supplements.
Background Poor diet and exposure to environmental toxins such as air pollution and food additives may lead to the depletion of certain vitamins, minerals and antioxidants making it desirable to supplement the diet with vitamins, minerals and other dietary supplements to restore the balance. Dietary supplements in daily dosage forms are common and provide the recommended daily allowance (RDA) for many vitamins and minerals in a single daily dosage form. Such products include: Sanatogen (Registered Trade Mark of Roche Consumer Health, UK) ONE-A-DAY multivitamins and minerals; Seven Seas (Registered Trade Mark of Seven Seas Health Care Ltd. , UK) ONE-A-DAY vitamin E; Once a day Effervescent vitamin C tablets (The Boots Company PLC, UK); One a day antioxidants vitamin formula (Marks and Spencer plc, UK). The common distinguishing feature of these products is that they are all in the form of a single daily dose. Other products which are fortified with dietary supplements include breakfast cereals. Again these products are intended to be consumed in a single daily serving and often contain a source of vitamin and mineral supplements.
Currently preferred methods for the administration of dietary supplements include single vitamin or mineral formulations, multi-vitamin formulations,, multi-vitamin formulations with added minerals, and multivitamin 2 formulations with antioxidants. These formulations take the form of tablets,, effervescent tablets, capsules, oils, and drinks.
US patent 5654011 describes dietary supplements for women to prevent or reduce health risks associated with pre-menopause, menopause and postmenopause life stages.
US patent 4599234 describes dietary supplements with selenium, butylated hydroxytoluene and beta-carotene for negating the effects of chemical 10 carcinogens in lower animals.
US patent 4833128 describes dietary supplements for suppression of appetite.
15US patent 5560928 describes a method and composition of providing dietary supplements in a single daily dose for immediate and sustained release.
US patent 4576932 describes a dietary supplement for the control of insulin and inhibition of insulin-rebound effects.
US patent 4897380 describes compositions relating to a daily dietary supplement for treating disorders responsive to treatment with serotoninUS patent 5569477 describes a chewing gum containing vitamins or other 25 active materials.
Dietary supplements are desirable to alleviate the potential effects caused by insufficient or poor dietary consumption of necessary vitamins and minerals and exposure to air and chemical pollutants, including tobacco smoke, 3 which may deplete the body of certain vitamins, minerals and antioxidants. Detrimental effects can- occur in people exposed to environmental pollutants, this may be prevented by supplementation of the diet with vitamin C or other vitamins. Potential sources of environmental pollutants and toxins are alcohol, air pollution, sunlight, pesticides, chemical food additives, and tobacco smoke.
Tobacco smoke is a significant source of chemical pollutants such as free radicals, carcinogens and irritants. Smoking is an habitual activity that has been shown to correlate with increased risks of developing cancers, heart and lung diseases and vascular disorders. The estimated disease and death rate attributed to smoking is substantial. It has been estimated that between - 50% of smokers die from smoking-related diseases (Adweek Southwest, October 1997. p33). Recently the WHO estimated that there are 1. 1 billion smokers, and that 500 million of these people will die from smoking related diseases if current trends continue. Figures for the USA estimate that 20% of deaths in the USA are smoking related and that smokers have a much increased chance of dying prematurely (Disease Weekly Plus, June 1997). The future trend for smoking related disease and death estimates that by 2025 10 million people will die of smoking related diseases (Independent, August 1997, p9).
Tobacco smoke is composed of two phases, gas and tar phases. Both contain high levels of oxidants, free radicals, nitrogen oxides and other potentially toxic chemicals, all of which may be detrimental to human health. The effects caused or mediated by the products of tobacco smoking may be short-lived acute events but can develop into chronic long-term events or diseases and even death.
4 Cigarette tar can induce DNA single strand breakage which is synergistically enhanced in the presence of nitric oxide (NO). The effects can be prevented by superoxide dismutase, or N-acetyl cysteine. However, hydoxy-radical scavengers such as DMSO were not shown to inhibit strand breakage (Yoshie, Y and Ohshima, H. (1997). Carcinogenesis. 18:1359 1361). NO can be formed in the lung by NO synthase, and in the presence Of 02-, generated by compounds such as catechol and 1,4-hydroquinone in tar, may react with the NO to form peroxynitrite which can contribute to lung damage and smoking related disease. (Yoshie, Y and Ohshima, H.
(1997). Carcinogenesis. 18:1359-1363.) Smoking tobacco is associated with increased risk of lung cancer, bladder cancer, hepatocellular carcinoma (Hietanen, E. et al. (1997) Environ. Health Perspectives. 105:749-754) and ulcer perforation (Svanes, C. et al. (1997) Gut. 41:177-180). The cervical mucus of women smokers has been reported to contain a higher amount of a tobacco specific carcinogen (a nitrosamine), which has been related to DNA damage in the cervical epithelium. The increased levels of smoking related nitrosamines may be linked to cervical cancer. (Prokopczyk,B. et al. (1997). Journal of the National Cancer Institute. 89:868-873).
Cigarette smoking has also been reported to have a prothrombotic effect. This may manifest as increased risks to health due to unwanted thrombosis leading to strokes or heart attacks. Smoking causes leukocyte adhesion to endothelial cells and leads to leukocyte-platelet aggregates. This phenomenon is thought to be caused by platelet activating factor (PAF)like mediators created by oxidative modification of lipids in smokers. Supplementation of the diet with vitamin C prevented the accumulation of the PAF-like lipids and formation of platelet aggregates. (Lehr, H. et al. (1997) Journal of Clinical Investigation. 99: 2358-2364).
There is also evidence to suggest that passive smoking carries a 30% greater risk of developing heart disease. This is approximately half the risk of a 20 a day smoker, but from only 1 % of the exposure. Lung cancer risk is also increased by 26% for passive smokers, who also have increased blood and urine levels of tobacco specific carcinogens. (Cancer Weekly Plus. November 1997).
Currently preferred methods for inhibition of the harmful effects associated with smoking tobacco include cessation of smoking, replacement of nicotine through the use of transdermal patches or tablets, substitution of the smoking habit with another habit, and use of filters to remove potentially 15 harmful agents present in tobacco smoke and tar.
US patent 4832994 describes the use of a lozenge containing a silver compound and a sweetener that has an unpleasant taste upon smoking. The use is based on the generated bad taste dissuading the smoker from smoking.
US patent 3876804 describes a chewing gum containing a silver salt and an ammonium compound which develops an unpleasant taste on smoking. The use is based on the generated bad taste dissuading the smoker from smoking.
US patent 4276890 describes a method for inhibiting the desire to smoke by administering a gamma pyrone compound to the smoker throughout the day.
6 US patent 5560379 describes a dental cleaning instrument or flosser that may be prepared with embedded microspheres containing anti-smoking agents.
US patent 5487902 describes a chewing gum composition containing an active agent including anti-smoking agents.
Supplementation of smokers diets with vitamins, antioxidants and minerals is desirable to ensure that vitamins, antioxidants and minerals that may be depleted by pollutants and toxins in tobacco smoke are replenished by the dietary supplement. Depleted levels of these substances may render smokers susceptible to cellular damage by the pollutants in tobacco smoke which may lead to ill health and disease. For example, tobacco smoke may lead to depleted antioxidant defences in smokers, which renders the smokers susceptible to the pro-oxidant chemicals present in tobacco smoke. Supplementation of the smokers diet with vitamins, antioxidants or minerals will help maintain a healthy level of defence against the prooxidants present in tobacco smoke. If these supplements are taken at regular intervals, for example just prior to, during or after smoking then the body's defences will be regularly bolstered at times when the tobacco smoke is depleting and overwhelming the defences and causing cellular damage. Additionally, small regular doses of supplements is generally regarded as being of greater benefit than large single doses.
An additional problem with the consumption of dietary supplements is that as they are usually in the form of a single daily dose, consumers often forget to take the supplements on a daily basis and thus negate much of the benefit derived from regular consumption of the supplements. Therefore, association of consuming a dietary supplement with another regular act, 7 such as smoking, will help to ensure compliance with regular consumption and help to maintain a healthy balance of the vitamins, antioxidants and minerals to prevent cellular damage and ill health due to their depletion and to help the body neutralise ingested pollutants such as tobacco smoke.
Essential technical features The present invention describes preparations in the form of confectionery or other edible forms fortified with dietary supplements which may be taken at any time. Each edible unit dosage form may contain from 1 to 20% of the recommended daily allowance of the dietary supplements, such that multiple units of the dosage form may be consumed per day, each unit contributing a proportion of the recommended daily allowance (RDA) of the dietary supplement. It can take the fonn of a sweet (confectionery), lozenge, pastille, chewing gum, nougat, toffee, tablet or capsule that can be chewed, sucked or swallowed. The preparation may contain vitamins, minerals, antioxidants or other dietary supplements. The supplements may include any substance or supplement thought to impart a benefit to the consumer.
However, preferably the preparation is in the form of a chewing gum or tablet which is encouraged to be taken prior to, during or after smoking tobacco. This will ensure that a habit of association will be formed, linking the use of the preparation with the habit of smoking. This may have the effect of ensuring or encouraging use of the preparation on a regular basis which is thought to be more beneficial than single dose therapies.
Preferably, the preparation contains antioxidants, vitamins and minerals (in the range of 1 % to 20% of the recommended daily allowance of each supplement per single edible unit) beneficial for the treatment, alleviation or prevention of smoking related diseases, disorders, conditions or ailments. Preferably, these substances may include vitamin C, vitamin E, vitamin B2, 8 beta carotene,, zinc, folic acid and other supplements thought to impart a benefit to smokers. Preferably, the preparation may contain agents that freshen breath or otherwise mask the smell of malodorous breath such as bad breath caused by smoking tobacco. Preferably, the breath freshening agents will be mint flavours such as peppermint or spearmint or mixtures of mint oils. The preparation may also contain agents that improve the taste or enhance the palatability of the preparation.
An alternative preferred embodiment of the present invention may take the form of preparations for pre-menopause, menopause and post-menopause dietary supplementation. Such preparations may be fortified with supplements suitable for the life stages described such as folic acid, calcium, vitamin E and vitamin D. Further embodiments of the present invention may be formulated for elderly people, active people, passive smokers, people exposed to environmental pollution, children and other life stages and lifestyles.
Without wishing to be bound by any theory, it is thought that antioxidants, vitamins and minerals are beneficial to the treatment, alleviation or prevention of smoking related diseases, disorders, conditions or ailments by supplementing the body's natural defences against toxic and pro- oxidant substances present in tobacco smoke and other pollutants, and by directly reacting with the toxins and pro-oxidants to render them less harmful. It is the presence of tobacco and pollution derived toxins that may lead to tissue damage, cellular damage and sub-cellular damage. For example, pro-oxidant species present in tobacco smoke and other pollutants may directly or indirectly lead to the damage or re-arrangement of DNA or the activation of oncogenes. This may lead to the development of a cancer. Supplementation 9 with antioxidants, vitamins and minerals may prevent this cascade resulting in oncogenesis.
Alternatively, pro-oxidants and other toxins present in tobacco smoke and other pollutants may enter the blood stream and lead to damage and activation of the endothelial cells lining the blood vessels. The endothelial cells become more adherent as a consequence due to the expression of adhesion molecules on their surface. The endothelial cells also secrete proinflammatory cytokines into the blood stream and surrounding tissues. This may result in thrombosis or increased risk of thrombosis, plaque formation on the blood vessel walls, fibrosis of the surrounding tissue. These consequences may result in poor or blocked blood flow leading to ischaemia, anoxia, cell damage and tissue necrosis. If this occurs in coronary arteries or other vessels supplying the heart then a heart attack may result. If this occurs in the brain then a stroke may be the result. If this sequence of events occurs in the peripheral vasculature then peripheral vascular disease may result. All of these outcomes have potentially life threatening or chronic long term health implications. Therefore, inhibition or prevention of these outcomes due to smoking or pollution is desirable. Vitamins, antioxidants and minerals can inhibit or help prevent key components of the above pathologies, or supplement the host defences to inhibit or minimise the initiation of the pathologies described.
The following examples illustrate the invention described above.
Example 1. Fortified smokers chewing gum. This preparation is formulated into a chewing gum for use before, during or after smoking. It is intended for smokers and recent ex-smokers to provide a combination of vitamins, antioxidants and minerals that may benefit the health of the individuals by supplementing the body's natural defences against the harmful effects of tobacco smoke. It is also intended to provide freshening of the breath by the addition of mint oils to the formulation. The manufacture of chewing gum and the use of gum base in said manufacture is well known to those skilled in the art, and may be found in US patent number 4238475 (to Witzel et al.), US patent number 4671961 (to Mansukh et al.) and 'Sugar confectionery and chocolate manufacture' (R.Lees and E.B.Jackson, 1992). A chewing gum formulation is prepared containing mint oils as breath fresheners and the active ingredients in the proportions stated below. Active ingredients are expressed as percent of RDA in each edible unit. One unit represents one stick, tablet or ball of chewing gum.
Active ingredient Amount %RDA per unit Vitamin E 2mg 20% Vitamin C 12mg 20% Riboflavin 80gg 5% Zinc 0.75mg 5% Vitamin B 12 50ng 5% Folic acid 20pig 10% Manganese 75gg No RDA Copper 25gg No RDA Selenium logg No RDA Beta carotene lmg No RDA 11 Example 2 Fortified smokers breath freshener (tablet). This preparation is formulated into a suckable sweet or tablet for use before, during or after smoking. It is intended for smokers and recent ex-smokers to provide a combination of vitamins, antioxidants and minerals that may benefit the health of the individuals by supplementing the body's natural defences against the harmful effects of tobacco smoke. It is also intended to provide freshening of the breath by the addition of mint oils to the formulation.
Tablets incorporating the composition of the present invention can be manufactured by well known tableting methods as known by those skilled in the art and described in 'Sugar confectionery manufacture' (Ed. E.B. Jackson, 1990). A tablet formulation is prepared containing mint oils as breath fresheners and the active ingredients in the proportions stated below.
Active ingredients are expressed as percent of RDA in each edible unit. One unit represents one tablet.
Active ingredient Amount.%RDA per unit Vitamin E 2mg 20% Vitamin C 12mg 20% Riboflavin 80pg 5% Zinc 0.75mg 5% Vitamin B 12 50ng 5% Folic acid 20gg 10% Manganese 75gg No RDA Copper 25gg No RDA Selenium logg No RDA Beta carotene Img No RDA 12 The base composition of the tablet may consist of sugar and glucose syrup as base materials and sweeteners, modified starch as a binding agent, stearic acid as a lubricant and mint oils as flavouring in proportions suitable to produce a consistent manufacturing process and product.
Example 3 Fortified smokers sugar-free chewing gum. This preparation is formulated into a chewing gum as described in Example 1 above, except that sweetening of the preparation is achieved by the 10 addition of a suitable amount of a low calorie sweetening agent.
Example 4 Fortified smokers sugar-free breath freshener (tablet). This preparation is formulated into a suckable sweet or tablet as described in Example 2 above, except that sweetening of the preparation is achieved by the addition of a suitable amount of a low calorie sweetening agent.
Example 5
Fortified chewing gum for general dietary supplementation.
This preparation is formulated as described in Example 1 or Example 3 above. except that the active ingredients are those listed below. The chewing gum is manufactured such that each edible unit of chewing gum contains about 8% of the RDA for each of the active ingredients listed below. The chewing gum is formulated for use by people who desire to supplement their diet with a general multi-vitamin, antioxidant and mineral preparation in a form that allows multiple doses to be taken throughout the day. The preparation may benefit the health of the individuals by supplementing the body's natural defences against the harmful effects of environmental 13 pollution, and by supplementing poor dietary intake of beneficial vitamins, antioxidants and minerals.
Active ingredient Vitamin D Calcium Vitamin A Vitamin E Vitamin C Thiamin (vitamin B) Riboflavin (vitamin B2) Niacin Vitamin B6 Folic acid Vitamin B12 Biotin Pantothenic acid Iron Magnesium Zinc Iodine Beta carotene Amount 0Agg 64mg 64gg 0.8mg 4.8mg 0. 1 12mg 0. 128mg 1.44mg 0.16mg 16gg 80ng 12gg 0.48mg 1. 12mg 23.5mg 1.2mg 12gg 32gg 14
Claims (1)
- Claims1. A preparation in edible unit dosage form comprising one or more substances beneficial for the treatment, alleviation or prevention of 2.6.smoking related diseases, disorders, conditions, or ailments, other than nicotine or a nicotine substitute, characterised in that each edible unit contains from 1 to 20% of the adult recommended daily allowance of said one or more substances. The preparation according to claim 1 wherein the preparation is in the form of, but not restricted to, tablets, lozenges, pastilles, capsules, boiled sweets, gum, biscuits, cookies, cakes, pastries, aerosol, mouthwash, toothpaste, liquid or other confectionery, food, drink, personal hygiene or other such presentations skilled to those in the art 3. A preparation according to claim 1 or claim 2 wherein each edible unit comprises from 2 to 10% of the adult recommended daily allowance of said one or more substances. The preparation according to any preceding claim, wherein each said edible unit contains from 4 to 8% of said adult recommended daily allowance of said one or more substances. The preparation according to any preceding claim wherein the preparation taken or consumed before, during or after smoking. The preparation according to any preceding claim wherein the preparation is taken or consumed immediately prior to smoking The preparation according to any preceding claim wherein the preparation is taken or consumed during smoking 8. The preparation according to any preceding claim wherein the preparation is taken or consumed immediately after smoking 9. The preparation according to any preceding claim wherein the preparation additionally contains one or more substances selected from the group consisting of (with adult RDA in parenthesis) vitamin E (10mg), vitamin C (60mg), folic acid (200ig), zinc and zinc salts (1 5mg), magnesium and magnesium salts (3 00mg), selenium and selenium salts (no RDA), vitamin D (5Rg), calcium (800mg), vitamin A (800 ptg), Thiamin (vitamin B,, 1Amg), riboflavin (vitamin B2, 1. 6mg), niacin (1 8mg), vitamin B6(2mg), vitamin B12 (1 gg), biotin (0. 15mg), pantothenic acid (6mg), iron (1 4mg), iodine (150 Rg), beta carotene (no RDA), manganese (no RDA), copper (no RDA), free radical scavengers, sulphydryl agents, DNA protecting agents, salts, energy supplements, electrolytes, antacids and other dietary supplements, vitamins, antioxidants and minerals, or other such substances obvious to those skilled in the art.10. A package containing a plurality of preparations in unit dosage form according to any preceding claim.11. A preparation in edible unit dosage form fortified with one or more substances or dietary supplements, characterised in that each edible unit contains from 1 to 20% of the adult recommended daily allowance of said one or more substances.12. The preparation according to claim 11 wherein the preparation is in the form of, but not restricted to, tablets, lozenges, pastilles, capsules, boiled sweets, gum, biscuits, cookies, cakes, pastries, aerosol, mouthwash, toothpaste, Hquid or other confectionery, food, drink, personal hygiene or other such presentations skilled to those in the art 13. A preparation according to claim 11 or claim 12 wherein each edible unit comprises from 2 to 10% of the adult recommended daily allowance of said one or more substances.14. The preparation according to any preceding claim, wherein each said edible unit contains from 4 to 8% of said adult recommended daily allowance of said one or more substances.16 15. The preparation according to any preceding claim wherein the preparation additionally contains one or more substances selected from the group consisting of (with adult RDA in parenthesis) vitamin E (1 Omg), vitamin C (60mg), folic acid (20OpLg), zinc and zinc salts (15mg), magnesium and magnesium salts (300mg), selenium and selenium salts (no RDA), vitamin D (5 pig), calcium (800mg), vitamin A (800 ptg), Thiamin (vitamin B,, 1Amg), riboflavin (vitamin B2, 1.6mg), niacin (1 8mg), vitamin B6(2mg), vitamin B12 (1 gg), biotin (0. 15mg), pantothenic acid (6mg), iron (1 4mg), iodine (15 0 PLg), beta carotene (no RDA), manganese (no RDA), copper (no RDA), free radical scavengers, sulphydryl agents, DNA protecting agents, salts, energy supplements, electrolytes, antacids and other dietary supplements, vitamins, antioxidants and minerals, or other such substances obvious to those skilled in the art.16. The preparation according to any preceding claim wherein the preparation additionally contains one or more substances that improve the palatability and taste of the preparation. Such substances may include, but are not restricted to, spearmint, peppermint, mint, menthol, camphor, eucalyptus, fruit flavours, sweetening agents, texture enhancers and antacids or other such substances obvious to those skilled in the art.17. The preparation according to any preceding claim wherein the preparation additionally contains breath freshening or odour masking agents.18. The preparation according to any preceding claim wherein the preparation contains one or more substances or dietary supplements for the treatment or prevention of periodontal related disorders and diseases.17 19. A preparation substantially as described herein with reference to claims 1 to 18.20. A package containing a plurality of preparations in unit dosage form according to any preceding claim.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9811908A GB2337933A (en) | 1998-06-04 | 1998-06-04 | Treating or prophylaxis of smoking related diseases |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9811908A GB2337933A (en) | 1998-06-04 | 1998-06-04 | Treating or prophylaxis of smoking related diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
GB9811908D0 GB9811908D0 (en) | 1998-07-29 |
GB2337933A true GB2337933A (en) | 1999-12-08 |
Family
ID=10833120
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB9811908A Withdrawn GB2337933A (en) | 1998-06-04 | 1998-06-04 | Treating or prophylaxis of smoking related diseases |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB2337933A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103932386A (en) * | 2014-03-22 | 2014-07-23 | 南通蛇类治疗研究所 | Selenium enrichment plant low-harm element cigarette |
RU2573293C2 (en) * | 2010-03-26 | 2016-01-20 | Филип Моррис Продактс С.А. | Inhibition of irritating sensations in process of non-smoking tobacco products consumptions |
CN108185507A (en) * | 2018-01-04 | 2018-06-22 | 中国烟草总公司广东省公司 | A kind of tobacco chewable tablets rich in selenium |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0205133A1 (en) * | 1985-06-14 | 1986-12-17 | Marie Luise Dr. Schicht | Plastic chewing mass based on chewing gum |
WO1991018593A1 (en) * | 1990-05-16 | 1991-12-12 | Board Of Regents, The University Of Texas System | Formula and method for the prevention and treatment of hypercholesterolemia and cellular hyperproliferative disorders |
EP0669132A1 (en) * | 1994-02-23 | 1995-08-30 | van der Kraaij, Antonius Marinus Maria | Pharmaceutical composition of vitamin E and acetylsalicylate for treatment and prevention of atherosclerosis |
WO1997031546A1 (en) * | 1996-02-29 | 1997-09-04 | Nutri Pharma As | Composition and its use as a food supplement or for lowering lipids in serum |
-
1998
- 1998-06-04 GB GB9811908A patent/GB2337933A/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0205133A1 (en) * | 1985-06-14 | 1986-12-17 | Marie Luise Dr. Schicht | Plastic chewing mass based on chewing gum |
WO1991018593A1 (en) * | 1990-05-16 | 1991-12-12 | Board Of Regents, The University Of Texas System | Formula and method for the prevention and treatment of hypercholesterolemia and cellular hyperproliferative disorders |
EP0669132A1 (en) * | 1994-02-23 | 1995-08-30 | van der Kraaij, Antonius Marinus Maria | Pharmaceutical composition of vitamin E and acetylsalicylate for treatment and prevention of atherosclerosis |
WO1997031546A1 (en) * | 1996-02-29 | 1997-09-04 | Nutri Pharma As | Composition and its use as a food supplement or for lowering lipids in serum |
Non-Patent Citations (5)
Title |
---|
Abstracts of CN 1138428 A (Y. Wang) * |
Abstracts of DE 19649730 A (Eu Rho Pharma GmbH) * |
Abstracts of DE 4312071 A (A. Wagner) * |
Abstracts of FR 2693876 A (Vani Soc Civ.) * |
Abstracts of JP 60062947 A (Y. Hayashi) * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2573293C2 (en) * | 2010-03-26 | 2016-01-20 | Филип Моррис Продактс С.А. | Inhibition of irritating sensations in process of non-smoking tobacco products consumptions |
US10117453B2 (en) | 2010-03-26 | 2018-11-06 | Philip Morris Usa Inc. | Inhibition of sensory irritation during consumption of non-smokeable tobacco products |
US11129405B2 (en) | 2010-03-26 | 2021-09-28 | Philip Morris Usa Inc. | Inhibition of sensory irritation during consumption of non-smokeable tobacco products |
CN103932386A (en) * | 2014-03-22 | 2014-07-23 | 南通蛇类治疗研究所 | Selenium enrichment plant low-harm element cigarette |
CN103932386B (en) * | 2014-03-22 | 2015-12-30 | 南通蛇类治疗研究所 | The low harmful element cigarette of selenium-enriched plant |
CN108185507A (en) * | 2018-01-04 | 2018-06-22 | 中国烟草总公司广东省公司 | A kind of tobacco chewable tablets rich in selenium |
CN108185507B (en) * | 2018-01-04 | 2020-12-08 | 中国烟草总公司广东省公司 | Selenium-rich tobacco chewable tablet |
Also Published As
Publication number | Publication date |
---|---|
GB9811908D0 (en) | 1998-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5922346A (en) | Antioxidant preparation | |
AU739194B2 (en) | Intra-oral antioxidant preparations | |
US6845777B2 (en) | Composition to reduce or quit smoking addiction | |
US20160213624A1 (en) | Composition, Commericial Product and Method for Treating Cannabis Toxicity | |
KR100516341B1 (en) | Compositions for regulating desire for smoking | |
JPS62503033A (en) | Solid oral composition for caries prevention | |
KR20130029067A (en) | Inhibition of undesired sensory effects by the compound camphor | |
EP1508335B1 (en) | Compositions comprising a cocoa fraction for use in the treatment of periodontitis caused by bacteria belonging to genus porphyromonas, prevotella, fusobacterium or actinobacillus | |
KR101930386B1 (en) | Adjuvant composition for quit smoking and oral hygiene products containing the same | |
GB2337933A (en) | Treating or prophylaxis of smoking related diseases | |
Vikneshan et al. | Smokeless tobacco and its adverse effects on oral cavity-an overview | |
RU2282447C2 (en) | Nicotine-containing pharmaceutical composition and its using | |
US9198943B2 (en) | Silene capensis for inhibiting cravings | |
KR101126279B1 (en) | Composition of mixed essential oils which is effective for stop smoking and its utiliztion | |
JP2003192585A (en) | Oral composition | |
JP2009286749A (en) | Solid material for oral cavity hygiene | |
WO2004095951A2 (en) | Food products comprising natural extracts or fragrances of plants together with aminoacids and use thereof for fighting smoke addiction | |
RU2205636C1 (en) | Preparation for preventing harmful action of tobacco smoke and other combustion products | |
JPS6245239B2 (en) | ||
KR20100095746A (en) | Nicotine chewing gum compositions | |
CZ35793A3 (en) | Anti-smoking preparation | |
MXPA00005413A (en) | Oral antioxidant preparation comprising selenium and reduced glutathione | |
GB2362571A (en) | Compositions for curbing smoking | |
MXPA00000097A (en) | Intra-oral antioxidant preparations | |
JP2004224796A (en) | Agent for suppressing toxicity of acetaldehyde |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |